Amgen Q2 2024 Adj. EPS $4.97 Misses $5.01 Estimate, Sales $8.388B Beat $8.333B Estimate
Portfolio Pulse from Benzinga Newsdesk
Amgen (NASDAQ:AMGN) reported Q2 2024 adjusted EPS of $4.97, missing the $5.01 estimate, but achieved sales of $8.388 billion, surpassing the $8.333 billion estimate. Sales increased by 20.07% year-over-year.

August 06, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Amgen's Q2 2024 adjusted EPS of $4.97 missed the $5.01 estimate, but sales of $8.388 billion beat the $8.333 billion estimate, showing a 20.07% year-over-year increase.
The mixed results, with EPS missing but sales beating estimates and showing significant year-over-year growth, suggest a neutral short-term impact on the stock price. Investors may weigh the EPS miss against the strong sales performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100